Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
59
ACAD Quote, Financials, Valuation and Earnings
Last price:
$26.55
Seasonality move
:
15.5%
Day range:
$25.40 - $26.76
52-week range:
$13.40 - $26.76
Dividend yield:
0%
P/E ratio:
17.08x
P/S ratio:
4.27x
P/B ratio:
4.90x
Volume:
1.8M
Avg. volume:
1.6M
1-year change:
54.63%
Market cap:
$4.5B
Revenue:
$957.8M
EPS (TTM):
$1.55
Analysts' Opinion
-
Consensus RatingACADIA Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 6 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $29.05, ACADIA Pharmaceuticals, Inc. has an estimated upside of 9.43% from its current price of $26.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 35.97% downside risk from its current price of $26.55.
Fair Value
-
According to the consensus of 16 analysts, ACADIA Pharmaceuticals, Inc. has 9.43% upside to fair value with a price target of $29.05 per share.
ACAD vs. S&P 500
-
Over the past 5 trading days, ACADIA Pharmaceuticals, Inc. has overperformed the S&P 500 by 6.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ACADIA Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ACADIA Pharmaceuticals, Inc. has grown year-over-year revenues for 12 quarters straight. In the most recent quarter ACADIA Pharmaceuticals, Inc. reported revenues of $278.6M.
Earnings Growth
-
ACADIA Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter ACADIA Pharmaceuticals, Inc. reported earnings per share of $0.42.
Enterprise value:
3.7B
EV / Invested capital:
3.81x
Price / LTM sales:
4.27x
EV / EBIT:
39.19x
EV / Revenue:
3.53x
PEG ratio (5yr expected):
0.17x
EV / Free cash flow:
37.38x
Price / Operating cash flow:
45.18x
Enterprise value / EBITDA:
34.11x
Gross Profit (TTM):
$962.5M
Return On Assets:
22.31%
Net Income Margin (TTM):
24.94%
Return On Equity:
34.23%
Return On Invested Capital:
31.98%
Operating Margin:
12.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $631.9M | $929.2M | $1B | $250.4M | $278.6M | |
| Gross Profit | $605.7M | $851.3M | $962.5M | $231.5M | $257M | |
| Operating Income | -$154.4M | $112.2M | $94.4M | $31.6M | $35.8M | |
| EBITDA | -$149.9M | $124.5M | $108.5M | $34.2M | $38.7M | |
| Diluted EPS | -$0.91 | $0.77 | $1.55 | $0.20 | $0.42 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $640.9M | $521.6M | $499.2M | $788.3M | $1.1B | |
| Total Assets | $717.7M | $602.5M | $632.5M | $976.9M | $1.3B | |
| Current Liabilities | $88.2M | $116.6M | $209.6M | $343.9M | $356.6M | |
| Total Liabilities | $150.7M | $176.8M | $270.4M | $399.7M | $413.5M | |
| Total Equity | $567M | $425.7M | $362.2M | $577.2M | $917.3M | |
| Total Debt | $65.8M | $53.8M | $48.1M | $40.4M | $43M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$92.5M | $202.7M | $198.9M | $63.2M | $74.3M | |
| Cash From Investing | $14.6M | -$153M | -$124.5M | -$82.5M | -$79.4M | |
| Cash From Financing | $21.3M | $10.3M | $29.2M | $268K | $9.4M | |
| Free Cash Flow | -$132.6M | $202.7M | $99M | $63.2M | $73.9M | |
ACAD
Sector
Market Cap
$4.5B
$28.8M
Price % of 52-Week High
99.22%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-0.79%
-1.32%
1-Year Price Total Return
54.63%
-20.64%
Beta (5-Year)
0.670
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$25.11
200-day SMA
Buy
Level
$21.05
Bollinger Bands (100)
Buy
Level
21.76 - 25.04
Chaikin Money Flow
Buy
Level
25.2M
20-day SMA
Buy
Level
$24.01
Relative Strength Index (RSI14)
Buy
Level
72.63
ADX Line
Buy
Level
27.52
Williams %R
Sell
Level
-5.3165
50-day SMA
Buy
Level
$22.52
MACD (12, 26)
Buy
Level
0.88
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
264.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.0256)
Buy
CA Score
(Annual)
Level (0.7808)
Sell
Beneish M-Score
(Annual)
Level (-1.8682)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-3.0532)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, ACAD has received 9 Buy ratings 6 Hold ratings, and 1 Sell ratings. The ACAD average analyst price target in the past 3 months is $29.05.
-
Where Will ACADIA Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ACADIA Pharmaceuticals, Inc. share price will rise to $29.05 per share over the next 12 months.
-
What Do Analysts Say About ACADIA Pharmaceuticals, Inc.?
Analysts are divided on their view about ACADIA Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ACADIA Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is ACADIA Pharmaceuticals, Inc.'s Price Target?
The price target for ACADIA Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $29.05 according to 16 Wall Street analysts, 9 of them rate the stock a Buy, 1 rates the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is ACAD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ACADIA Pharmaceuticals, Inc. is a Buy. 9 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACAD?
You can purchase shares of ACADIA Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ACADIA Pharmaceuticals, Inc. shares.
-
What Is The ACADIA Pharmaceuticals, Inc. Share Price Today?
ACADIA Pharmaceuticals, Inc. was last trading at $26.55 per share. This represents the most recent stock quote for ACADIA Pharmaceuticals, Inc.. Yesterday, ACADIA Pharmaceuticals, Inc. closed at $26.55 per share.
-
How To Buy ACADIA Pharmaceuticals, Inc. Stock Online?
In order to purchase ACADIA Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ACAD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ACAD
Sector
P/E ratio
17.08x
23.71x
PEG ratio
0.17x
-0.01x
P/B ratio
4.90x
1.84x
Price / LTM sales
4.27x
1.60x
Growth Metrics
ACAD
Sector
Revenue growth
11.28%
4.85%
Earnings growth
113.29%
11.15%
Revenue (5-year growth)
23.08%
6.45%
Earnings forecast
$0.15
-$0.20
Profitability
ACAD
Sector
Profitability FY 2024
$861M
$3.6M
Return on invested capital
31.98%
-30.98%
Return on assets
22.31%
-27.62%
Return on equity
34.23%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
4
Balance Sheet
ACAD
Sector
Total cash
$847M
$27.2M
Short term investments
$436.4M
$25.7M
Total assets
$1.2B
$79.7M
Long term debt
$43M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 87.95% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 2.04% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 1.27% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
